The clinical and economic burden of psoriasis

Managed Care Interface

Volumn 19, Issue 4, 2006, Pages 20-26

  Hazard, Elisabeth H ^a   Cherry, Spencer B ^a   Lalla, Deepa ^c,d   Woolley, J Michael ^b   Wilfehrt, Helen ^c   Chiou, Chiun Fang ^c  

^a ValueMedics Research   (United States)

^b Amgen   (United States)

^c AMGEN INC   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; BIOLOGICAL PRODUCT; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; KERATOLYTIC AGENT; METHOTREXATE; METHOXSALEN; RETINOID; VITAMIN D DERIVATIVE;

ABSENTEEISM; AGING; CATARACT; CLINICAL FEATURE; COST OF ILLNESS; CUTANEOUS PARAMETERS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; EMOTIONALITY; HUMAN; MEDLINE; MELANOMA; MENTAL STRESS; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN CANCER; SOCIAL PSYCHOLOGY; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

COST OF ILLNESS; HUMANS; PSORIASIS; UNITED STATES;

EID: 33646453071     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Stern RS, Nijsten T, Feldman SR, et al: Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-139.
2. Crown W: The cost of psoriasis. Manag Care 2003;12:10-13.
3. Fortune DG, Richards HL, Main CJ, et al: What patients with psoriasis believe about their condition. J Am Acad Dermatol 1998;39(2pt 1):196-201.
4. Koo J: Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-496.
5. Christophers E: Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-320.
6. Gelfand JM, Feldman SR, Stern RS, et al: Determinants of quality of life in patients with psoriasis: A study from the U.S. population. J Am Acad Dermatol 2004;51:704-708.
7. About psoriasis: Statistics. National Psoriasis Foundation (www.psoriasis.org/about/stats), February 2006.
8. Bell LM, Sedlack R, Beard CM, et al: Incidence of psoriasis in Rochester, Minnesota, 1980-1983. Arch Dermatol 1991;127:1184-1187.
9. National Psoriasis Foundation Benchmark Survey on Psoriasis and Psoriatic Arthritis. Portland, OR, National Psoriasis Foundation, 2004.
10. Lebwohl M: Psoriasis. Lancet 2003;361:1197-1204.
11. Griffiths CE: The immunological basis of psoriasis. J Eur Acad Dermatol Venereol 2003;17(suppl 2):1-5.
12. Barker JN: Genetic aspects of psoriasis. Clin Exp Dermatol 2001;26:321-325.
13. Facts: Psoriasis. Portland, OR, National Psoriasis Foundation, 2004.
14. Naysmith L, Rees JL: Psoriasis and its management. J R Coll Physicians Edinb 2003;33:104-113.
15. Fleischer Jr, AB, Feldman SR, Rapp SR: Introduction. The magnitude of skin disease in the United States. Dermatol Clin 2000;18:xv-xxi.
16. Tsankov N, Angelova I, Kazandjieva J: Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000;1:159-165.
17. American Academy of Dermatology Association: Guidelines of care for psoriasis. J Am Acad Dermatol 1993;28:632-637.
18. Krueger GG, Feldman SR, Camisa C, et al: Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43(2 pt 1):281-285.
19. Carlin CS, Feldman SR, Krueger JG, et al: A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 2004;50:859-866.
20. Langley RG, Ellis CN: Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004;51:563-569.
21. Crown WH, Bresnahan BW, Orsini LS, et al: The burden of illness associated with psoriasis: Cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004;20:1929-1936.
22. Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986.
23. Poikolainen K, Reunala T, Karvonen J: Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994;130:473-477.
24. Mills CM, Srivastava ED, Harvey IM, et al: Smoking habits in psoriasis: A case control study. Br J Dermatol 1992;127:18-21.
25. Koo J, Lee E, Lee CS, et al: Psoriasis. J Am Acad Dermatol 2004;50:613-622.
26. Sampogna F, Gisondi P, Melchi CF, et al: Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004;151:594-599.
27. Gladman DD: Psoriatic arthritis. Rheum Dis Clin North Am 1998;24:829-844.
28. Krueger G, Koo J, Lebwohl M, et al: The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-284.
29. Facts: Psoriatic Arthritis. Portland, OR, National Psoriasis Foundation, 2004.
30. Husted JA, Gladman DD, Farewell VT, et al: Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001;45:151-158.
31. Thumboo J, Uramoto K, Shbeeb MI, et al: Risk factors for the development of psoriatic arthritis: A population-based nested case control study. J Rheumatol 2002;29:757-762.
32. Margolis D, Bilker W, Hennessy S, et al: The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-783.
33. Stern RS: Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. N Engl J Med 1990;322:1093-1097.
34. Zachariae H, Sogaard H, Heickendorff L: Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies-a further 10-year follow-up. Dermatology 1996;192:343-346.
35. Wong BR, Josien R, Lee SY, et al: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997;186:2075-2080.
36. Shbeeb M, Uramoto KM, Gibson LE, et al: The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 2000;27:1247-1250.
37. Weiss SC, Kimball AB, Liewehr DJ, et al: Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512-518.
38. Heydendael VM, de Borgie CA, Spuls PI, et al: The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004;9:131-135.
39. Rapp SR, Feldman SR, Exum ML, et al: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41(3 pt 1):401-407.
40. Fleischer Jr AB, Rapp SR, Reboussin DM, et al: Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol 1994;102:967-969.
41. Feldman SR, Fleischer Jr AB, Reboussin DM, et al: The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996;106:183-186.
42. Finlay AY, Coles EC: The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995;132:236-244.
43. de Korte J, Sprangers MA, Members FM, et al: Quality of life in patients with psoriasis: A systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-147.
44. Uttjek M, Dufaker M, Nygren L, et al: Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol 2004;84:37-43.
45. Zachariae R, Zachariae H, Blomqvist K, et al: Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002;146:1006-1016.
46. Ersser SJ, Surridge H, Wiles A: What criteria do patients use when judging the effectiveness of psoriasis management? J Eval Clin Pract 2002;8:367-376.
47. Gottlieb AB, Chaudhari U, Baker DG, et al: The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): A comparison. J Drugs Dermatol 2003;2:260-266.
48. Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 1995;332:581-588.
49. Weinstein GD, White GM: An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993;28:454-459.
50. Menter MA, See JA, Amend WJ, et al: Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol 1996;34(2 Pt 1):315-321.
51. Koo J: Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results. J Am Acad Dermatol 1999;41(3 Pt 2):S25-S28.
52. Lindelof B, Sigurgeirsson B, Tegner E, et al: PUVA and cancer risk: The Swedish follow-up study. Br J Dermatol 1999;141:108-112.
53. Stern RS, Bagheri S, Nichols K: The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. J Am Acad Dermatol 2002;47:33-39.
54. McKenna KE, Stern RS: The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997;36(3 pt 1):388-394.
55. Stern RS: The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44(5):755-61.
56. Sterry W, Barker J, Boehncke WH, et al: Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004;151(suppl 69):3-17.
57. Cather JC, Menter A: Modulating T cell responses for the treatment of psoriasis: A focus on efalizumab. Expert Opin Biol Ther 2003;3(suppl 2):361-370.
58. Craze M, Young M: Integrating biologic therapies into a dermatology practice: Practical and economic considerations. J Am Acad Dermatol 2003;49(2 suppl):139-142.
59. National Population Estimates: Monthly Postcensal Resident Population, by Single Year of Age, Sex, Race, and Hispanic Origin, July 2002. Washington, DC, U.S. Census Bureau, 2004.
60. Consumer Price Index-All Urban Consumers. Washington, DC, U.S. Department of Labor, 2004.
61. Javitz HS, Ward MM, Farber E, et al: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850-860.
62. Pariser DM: Treating psoriasis patients with biologic agents. Manag Care 2003;12:50-57.
63. Weiss SC, Bergstrom KG, Weiss SA, et al: Quality of life considerations in psoriasis treatment. Dermatol Nurs 2003;15:120, 123-127.
64. Sander HM, Morris LF, Phillips CM, et al: The annual cost of psoriasis. J Am Acad Dermatol 1993;28:422-425.
65. Krueger GG, Bergstresser PR, Lowe NJ, et al: Psoriasis. J Am Acad Dermatol 1984;11(5 pt 2):937-947.
66. Kraning K, Odland GF: Psoriasis. J Invest Dermatol 1979;73:402-413.